Meet Neuland at CPHI India 2026 | Hall 2, Booth 2D38 | Yashobhoomi Convention Centre, New Delhi | 24-26 November 2026 Schedule a Meeting

About Us
Insights
Sustainability
Investors
Careers

CDMO Services
Generic APIs
Our Capabilities

A trusted CDMO partner providing integrated solutions for small molecules and peptides.

Quick Links

About Us
Our Capabilities
Generic APIs
CDMO Services
Peptide Development

Important Links

Stories
Sustainability
Investors
Careers
Glossary

Legal & Redressal

Terms and Conditions
Privacy Policy
Cookie Policy
Contact Us

Get in Touch

marketing@neulandlabs.com

11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-III, Road No. 82, Jubilee Hills, Hyderabad, 500033, Telangana, India.

Subscribe to our newsletter

Insights, updates and event news delivered to your inbox.

Signup For Our E-Newsletter

News & Announcements | Neuland Labs

Home
Insights
News

News

Latest press releases, corporate announcements, financial highlights, and operational updates from Neuland Labs.

Year:

Neuland Laboratories Achieves ISO 22301:2019 Certification for Business Continuity Management System (BCMS)

NEWS

Oct 27, 2026

Neuland Laboratories Achieves ISO 22301:2019 Certification for Business Continuity Management System (BCMS)

Neuland Accelerates Peptide Manufacturing Expansion with First Commercial Module Operational

NEWS

Sep 15, 2026

Neuland Accelerates Peptide Manufacturing Expansion with First Commercial Module Operational

NEWS

Aug 31, 2026

Neuland Laboratories Expands Sterile API Manufacturing Capacity Through Strategic Collaboration with Gland Pharma

Neuland to open $20m* dedicated Process Development facility with integrated kilo labs in Hyderabad

NEWS

Jun 15, 2026

Neuland to open $20m* dedicated Process Development facility with integrated kilo labs in Hyderabad

Saharsh Davuluri takes over as CEO & MD of Neuland and will lead the next phase of CDMO expansion

NEWS

Apr 1, 2026

Saharsh Davuluri takes over as CEO & MD of Neuland and will lead the next phase of CDMO expansion

LIR Life Engages with Neuland Labs to Advance Development of Cell Penetrating Peptides

NEWS

Jan 19, 2026

LIR Life Engages with Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP 1/GIP Peptide Platform

Mr. Sucheth Davuluri, Vice Chairman and Chief Executive Officer

NEWS

Nov 4, 2025

Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of Neuland Laboratories, has been elected as Third Vice President to the 2026 Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT).

Sword of Honour by British Safety Council

NEWS

Oct 22, 2025

Neuland Labs Manufacturing Unit-I has been awarded the prestigious Sword of Honour by British Safety Council for excellence in health and safety management systems

Unit I secured a Five Star Safety Rating

NEWS

Aug 29, 2025

News

Neuland Laboratories Achieves ISO 22301:2019 Certification for Business Continuity Management System (BCMS)

Neuland Accelerates Peptide Manufacturing Expansion with First Commercial Module Operational

Neuland Laboratories Expands Sterile API Manufacturing Capacity Through Strategic Collaboration with Gland Pharma

Neuland to open $20m* dedicated Process Development facility with integrated kilo labs in Hyderabad

Saharsh Davuluri takes over as CEO & MD of Neuland and will lead the next phase of CDMO expansion

LIR Life Engages with Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP 1/GIP Peptide Platform

Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of Neuland Laboratories, has been elected as Third Vice President to the 2026 Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT).

Neuland Labs Manufacturing Unit-I has been awarded the prestigious Sword of Honour by British Safety Council for excellence in health and safety management systems

Neuland Labs’ Manufacturing Unit I secured a Five-Star Safety Rating with an audit score of 92.08% from British Safety Council